ArticleACS infectious diseases2026
Development of Semisynthetic Blasticidin S Analogs with Potent and Fast-Killing Antimalarial Activity.
Article in ACS infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Protein synthesis represents an attractive target space for the development of antimalarials with novel modes of action. Natural-product inhibitors of the eukaryotic 80S ribosome can have potent antimalarial activity but are often poorly selective due to mammalian cytotoxicity. Blasticidin S is a microbially produced natural product that broadly inhibits prokaryotic and eukaryotic protein synthesis by binding to the ribosomal peptidyl transferase center. In this study, we explored the potential for improving the antimalarial potency and selectivity of the blasticidin S scaffold with semisynthetic analogs that are modified at the C6' and C4 sites. The two best analogs were 2 orders of magnitude more potent than blasticidin S against Plasmodium falciparum drug-sensitive and -resistant lines while displaying low cytotoxicity toward mammalian cells. These analogs exhibited improved kinetics of inhibition of protein synthesis in cultured parasites and arrested asexual development after the onset of plasmodial surface anion channel expression, a transporter required for nutrient acquisition and blasticidin S uptake. They also exhibited a dramatically improved speed of killing over blasticidin S. Molecular docking analysis revealed that these analogs are able to form more interactions with the P. falciparum ribosomal peptidyl transferase center than is blasticidin S, which is consistent with their increased potency. Together, these studies demonstrate the feasibility of generating blasticidin S analogs with potent antimalarial activity and provide a roadmap for further development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.